Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose‐limiting toxicity (DLT) in colon can...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Raafi, Baracos, Vickie E., Sawyer, Michael B., Bianchi, Laurent, Roberts, Sarah, Assenat, Eric, Mollevi, Caroline, Senesse, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831278/
https://www.ncbi.nlm.nih.gov/pubmed/26814378
http://dx.doi.org/10.1002/cam4.621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831278/
https://www.ncbi.nlm.nih.gov/pubmed/26814378
http://dx.doi.org/10.1002/cam4.621

Ejemplares similares